As a result, many health systems worldwide have approved the reimbursement of these tests for ER+/HER2- breast cancer patients since 2006, but reimbursement in Italy was not approved until July 2019 in Lombardy [19] and then later countrywide in May 2021. Here, ERBB2 is linked to breast carcinoma.